|
MX359634B
(es)
|
2011-12-21 |
2018-10-03 |
Novira Therapeutics Inc |
Agentes antivirales contra la hepatitis b.
|
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
|
UY34992A
(es)
|
2012-08-28 |
2014-02-28 |
Janssen R & D Ireland |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
|
JP2015526520A
(ja)
*
|
2012-08-31 |
2015-09-10 |
プリンシピア バイオファーマ インコーポレイテッド |
Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
|
|
PT2961732T
(pt)
|
2013-02-28 |
2017-06-26 |
Janssen Sciences Ireland Uc |
Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014161888A1
(en)
|
2013-04-03 |
2014-10-09 |
Janssen R&D Ireland |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
PT2997019T
(pt)
|
2013-05-17 |
2018-11-21 |
Janssen Sciences Ireland Uc |
Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
UA118680C2
(uk)
|
2013-07-25 |
2019-02-25 |
ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі |
Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
EP3060547B1
(en)
|
2013-10-23 |
2017-10-11 |
Janssen Sciences Ireland UC |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
WO2015085482A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Novartis Ag |
Egfr inhibitor forms
|
|
WO2015083059A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Forms of the egfr inhibitor
|
|
WO2015081463A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Egfr inhibitor forms
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
RU2702109C1
(ru)
|
2014-02-05 |
2019-10-04 |
Новира Терапьютикс, Инк. |
Комбинированная терапия для лечения инфекций вгв
|
|
EA035848B1
(ru)
|
2014-02-06 |
2020-08-20 |
Янссен Сайенсиз Айрлэнд Юси |
Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
|
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CA2943220C
(en)
*
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
EP3119784B1
(en)
|
2014-03-20 |
2020-07-22 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
WO2016055916A1
(en)
|
2014-10-06 |
2016-04-14 |
Novartis Ag |
Therapeutic combination for the treatment of cancer
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
CA2979215A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
AU2016232801A1
(en)
|
2015-03-19 |
2017-10-12 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
CN108012529A
(zh)
*
|
2015-05-15 |
2018-05-08 |
诺华股份有限公司 |
治疗egfr突变的癌症的方法
|
|
BR112017024337A2
(pt)
*
|
2015-05-22 |
2018-07-31 |
Novartis Ag |
composições farmacêuticas
|
|
CN107849034B
(zh)
*
|
2015-06-30 |
2021-09-03 |
达纳－法伯癌症研究所公司 |
Egfr抑制剂及其使用方法
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
US20180177872A1
(en)
*
|
2015-07-29 |
2018-06-28 |
Yong Jia |
Combination of PD-1 antagonist with an EGFR inhibitor
|
|
EP3350170B1
(en)
*
|
2015-09-18 |
2022-01-26 |
Merck Patent GmbH |
Heteroaryl compounds as irak inhibitors and uses thereof
|
|
US10590108B2
(en)
|
2015-09-23 |
2020-03-17 |
Capella Therapeutics, Inc. |
Benzimidazoles for use in the treatment of cancer and inflammatory diseases
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
AR106192A1
(es)
|
2015-09-29 |
2017-12-20 |
Novira Therapeutics Inc |
Formas cristalinas de un agente antiviral contra la hepatitis b
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
KR20240113606A
(ko)
|
2015-11-16 |
2024-07-22 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
KR102833068B1
(ko)
|
2015-12-17 |
2025-07-14 |
노파르티스 아게 |
Pd-1에 대한 항체 분자 및 그의 용도
|
|
WO2017175156A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
WO2017175144A1
(en)
|
2016-04-08 |
2017-10-12 |
Novartis Ag |
New therapeutic uses
|
|
SG11201808949SA
(en)
|
2016-04-15 |
2018-11-29 |
Novira Therapeutics Inc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
US20170321285A1
(en)
*
|
2016-05-03 |
2017-11-09 |
The Texas A&M University System |
Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CN107663170B
(zh)
*
|
2016-07-29 |
2020-02-11 |
广东东阳光药业有限公司 |
制备贝西沙星中间体化合物的方法
|
|
CA2939286A1
(en)
*
|
2016-08-17 |
2018-02-17 |
Pharmascience Inc. |
Spirocyclic containing compounds and pharmaceutical uses thereof
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
EP3555274A4
(en)
*
|
2016-12-13 |
2020-08-05 |
University of Pittsburgh - of The Commonwealth System of Higher Education |
METHODS OF TREATMENT OF CANCERS CONTAINING FUSION GENES
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
CN106946779A
(zh)
*
|
2017-02-13 |
2017-07-14 |
广州仁恒医药科技股份有限公司 |
一种r‑3‑氨基‑六氢氮杂*的制备方法
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
CU24606B1
(es)
|
2017-06-22 |
2022-06-06 |
Novartis Ag |
Moléculas de anticuerpo que se unen a cd73
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
KR20200019865A
(ko)
|
2017-06-22 |
2020-02-25 |
노파르티스 아게 |
암 치료에 사용하기 위한 il-1베타 결합 항체
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
MX2020001253A
(es)
|
2017-08-03 |
2020-07-13 |
Novartis Ag |
Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
|
|
EP3661516A1
(en)
|
2017-08-03 |
2020-06-10 |
Novartis AG |
Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
|
|
CN109721605B
(zh)
*
|
2017-10-31 |
2022-03-11 |
维眸生物科技（上海）有限公司 |
一种免疫细胞迁徙抑制剂
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019162323A1
(en)
|
2018-02-21 |
2019-08-29 |
Boehringer Ingelheim International Gmbh |
New benzimidazole compounds and derivatives as egfr inhibitors
|
|
WO2019175657A1
(en)
|
2018-03-14 |
2019-09-19 |
Janssen Sciences Ireland Unlimited Company |
Capsid assembly modulator dosing regimen
|
|
JP7399872B2
(ja)
|
2018-04-18 |
2023-12-18 |
ノバルティス アーゲー |
Ｃｎｓ転移の治療に使用するためのナザルチニブ
|
|
GEAP202215475A
(en)
*
|
2018-04-26 |
2022-07-11 |
Pfizer Inc |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2020012495A
(es)
|
2018-06-01 |
2021-02-15 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas.
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
CN109369620B
(zh)
*
|
2018-12-22 |
2020-04-14 |
山东大学 |
吡啶类化合物及其制备方法与抗胃癌应用
|
|
CN113454077A
(zh)
|
2019-02-22 |
2021-09-28 |
爱尔兰詹森科学公司 |
用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
|
|
CN111747931A
(zh)
|
2019-03-29 |
2020-10-09 |
深圳福沃药业有限公司 |
用于治疗癌症的氮杂芳环酰胺衍生物
|
|
MA55879A
(fr)
|
2019-05-06 |
2022-03-16 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
JP7590996B2
(ja)
*
|
2019-06-24 |
2024-11-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
EP4045506B1
(en)
*
|
2019-10-15 |
2025-07-23 |
Aucentra Therapeutics Pty Ltd |
Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
|
|
KR102267662B1
(ko)
*
|
2019-11-19 |
2021-06-22 |
한국화학연구원 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN115397421A
(zh)
|
2020-05-08 |
2022-11-25 |
诺华股份有限公司 |
包含tno155和那扎替尼的药物组合
|
|
EP4154891A4
(en)
*
|
2020-05-18 |
2023-12-06 |
Wellmarker Bio Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF RON MUTATION ASSOCIATED NON-SMALL CELL LUNG CANCER AND METHOD FOR THE USE THEREOF
|
|
WO2021235813A1
(ko)
*
|
2020-05-18 |
2021-11-25 |
웰마커바이오 주식회사 |
Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
|
|
US20230202992A1
(en)
*
|
2020-05-18 |
2023-06-29 |
Wellmarker Bio Co., Ltd. |
Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
CN113880804A
(zh)
*
|
2020-07-01 |
2022-01-04 |
微境生物医药科技(上海)有限公司 |
新型苯并咪唑化合物
|
|
WO2022081478A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
EP4237423B1
(en)
|
2020-11-02 |
2024-12-11 |
Boehringer Ingelheim International GmbH |
Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
|
|
MX2023005353A
(es)
|
2020-11-06 |
2023-05-22 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
|
WO2022245061A1
(ko)
*
|
2021-05-17 |
2022-11-24 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN115368378B
(zh)
*
|
2021-05-21 |
2024-11-19 |
深圳市塔吉瑞生物医药有限公司 |
取代的大环化合物及包含该化合物的组合物及其用途
|
|
EP4355330A1
(en)
|
2021-06-15 |
2024-04-24 |
Genentech, Inc. |
Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
|
|
US20240352021A1
(en)
*
|
2021-10-18 |
2024-10-24 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
KR102572664B1
(ko)
*
|
2022-02-07 |
2023-08-30 |
주식회사 인터엠 |
오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송
|
|
US20250214995A1
(en)
|
2022-04-28 |
2025-07-03 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209086A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds for treating cancer
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
CA3259195A1
(en)
*
|
2022-06-14 |
2023-12-21 |
Principia Biopharma Inc. |
TOLEBRUTINIB MANUFACTURING PROCESSES
|
|
TW202416963A
(zh)
*
|
2022-09-02 |
2024-05-01 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｇｆｒ抑制劑及其用途
|